Program
MT027
A development code. Also written as “MT027 cells suspension” and “Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3”.
Its studies are mostly in Brain Neoplasms · Neurologic Manifestations · Glioma · Pleural Effusion, Malignant, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Suzhou Maximum Bio-tech | 33 open or running | phase 1since Jun 11, 2024 | Jun 11, 2024 | none ahead |
| T-MAXIMUM Pharmaceutical | 22 open or running | phase 2since Jan 27, 2026 | Jan 27, 2026 | Dec 13, 2028phase 2 · NCT07386002 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 11, 2024First study: phase 1 study in Pleural Effusion, MalignantNew to Suzhou Maximum Bio-techSuzhou Maximum Bio-tech · NCT06726564 · 18 planned · China
- Dec 3, 20242 phase 1 studiesSuzhou Maximum Bio-tech · NCT06742593, NCT06737146
- Jan 27, 2026T-MAXIMUM Pharmaceutical's first study: phase 2 study in RecurrenceNew to T-MAXIMUM PharmaceuticalT-MAXIMUM Pharmaceutical · NCT07386002 · 40 planned · United States, Taiwan
- Oct 14, 2026Phase 2 study in Brain Metastases From Solid TumorsT-MAXIMUM Pharmaceutical · NCT07897799 · 40 planned · United States, Taiwan
Ahead
- Dec 13, 2028Primary completion: phase 2 study in RecurrenceT-MAXIMUM Pharmaceutical · NCT07386002
- Dec 20, 2029Primary completion: phase 2 study in Brain Metastases From Solid TumorsT-MAXIMUM Pharmaceutical · NCT07897799
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07897799Brain Metastases From Solid Tumors · United States, Taiwan | 2 | Not yet recruiting | T-MAXIMUM Pharmaceutical | Dec 20, 2029 | 40 |
| NCT07386002Recurrence · United States, Taiwan | 2 | Not yet recruiting | T-MAXIMUM Pharmaceutical | Dec 13, 2028 | 40 |
| NCT06737146Glioma · China | 1 | Not yet recruiting | Suzhou Maximum Bio-tech | Jun 30, 2026 | 12 |
| NCT06742593Neurologic Manifestations · China | 1 | Not yet recruiting | Suzhou Maximum Bio-tech | Dec 30, 2025 | 12 |
| NCT06726564Pleural Effusion, Malignant · China | 1 | Recruiting | Suzhou Maximum Bio-tech | May 2026 | 18 |
How it is read
Names in the registry
- “MT027 cells suspension”, 3 entries
- “Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3”, 2 entries
Codes read as this program: MT027.
Conditions, from the studies’ own filings
- Brain Neoplasms, 1 study
- Neurologic Manifestations, 1 study
- Glioma, 1 study
- Pleural Effusion, Malignant, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.